Original Article
Treatment of chronic myeloid leukemia: outcome of the tyrosine kinase inhibitors.
Kefi Salma , Ben Lakhal Raihane , Bchir Manel , Jabr Dorra , Ben Neji Hend , Berred Emna , Mansouri Raoudha , Achour Mariem , Ben Abdennebi Yosr , Kacem Karima , Menif Samia , Aissaoui Lamia , Meddeb Balkis.
The chronic myeloid leukemia (CML) is a myeloproliferative neoplasm eligible for targeted therapy with tyrosine kinase inhibitors (TKI). We report in our study the therapeutic outcomes of 173 patients treated for CML in the department of hematology in Aziza Othmana hospital Tunis Tunisia. The front line treatment with Imatinib a first generation TKI has achieved a complete hematological response, a complete cytogenetical response, a major molecular response and a molecular response>4 log in respectively, 95%, 70%, 64% and 40% of patients. The switch to a second generation TKI was indicated in 40% of the patients and has improved the outcomes. The 5-year overall survival (OS) and progression free survival (PFS) were respectively 90 and 91%. Our outcomes are comparable to the reported data and seems to be very encouraging.
Current Issue
